- Yu, Minjia;
- Zhou, Hao;
- Zhao, Junjie;
- Xiao, Nengming;
- Roychowdhury, Sanjoy;
- Schmitt, David;
- Hu, Bingqing;
- Ransohoff, Richard M;
- Harding, Clifford V;
- Hise, Amy G;
- Hazen, Stanley L;
- DeFranco, Anthony L;
- Fox, Paul L;
- Morton, Richard E;
- Dicorleto, Paul E;
- Febbraio, Maria;
- Nagy, Laura E;
- Smith, Jonathan D;
- Wang, Jian-an;
- Li, Xiaoxia
Low-grade systemic inflammation is often associated with metabolic syndrome, which plays a critical role in the development of the obesity-associated inflammatory diseases, including insulin resistance and atherosclerosis. Here, we investigate how Toll-like receptor-MyD88 signaling in myeloid and endothelial cells coordinately participates in the initiation and progression of high fat diet-induced systemic inflammation and metabolic inflammatory diseases. MyD88 deficiency in myeloid cells inhibits macrophage recruitment to adipose tissue and their switch to an M1-like phenotype. This is accompanied by substantially reduced diet-induced systemic inflammation, insulin resistance, and atherosclerosis. MyD88 deficiency in endothelial cells results in a moderate reduction in diet-induced adipose macrophage infiltration and M1 polarization, selective insulin sensitivity in adipose tissue, and amelioration of spontaneous atherosclerosis. Both in vivo and ex vivo studies suggest that MyD88-dependent GM-CSF production from the endothelial cells might play a critical role in the initiation of obesity-associated inflammation and development of atherosclerosis by priming the monocytes in the adipose and arterial tissues to differentiate into M1-like inflammatory macrophages. Collectively, these results implicate a critical MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases.